Red Cell Distribution Width Versus Presepsin (Soluble CD14) as a Prognostic Marker in Critically-ill Sepsis Patients

Comparison of Red Cell Distribution Width Versus Presepsin (Soluble CD14) for Prognosis Assessment in Sepsis Patients Admitted to the Intensive Care Unit

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03796715

Enrollment

200

Registered

2019-01-08

Start date

2018-08-01

Completion date

2018-12-24

Last updated

2019-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

sepsis, presepsin, red cell distribution width

Brief summary

Presepsin (soluble CD14 subtype) is a novel marker with growing body of evidence supporting its accuracy and value for the diagnosis of sepsis. Patients with sepsis showed higher Prsepsin levels compared to those with SIRS. In addition the increase in Prsepsin levels correlates well with sepsis severity. Red cell distribution width variations are increased in a variety of medical conditions such as congestive heart failure, acute myocardial infarction, pulmonary embolism, pneumonia, critical illness, and cardiac arrest , and is a predictor of mortality in the general population. we aim to compare between Presepsin (soluble CD14) and RDW as prognostic markers in critically-ill patients with sepsis.

Interventions

DIAGNOSTIC_TESTRed Cell Distribution Width (RDW)

A total of 100 sepsis patients, Red Cell Distribution Width (RDW) was used as prognostic marker.

DIAGNOSTIC_TESTPresepsin (sCD14-ST)

: A total of 100 sepsis patients, Presepsin (sCD14-ST) was used as prognostic marker.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Male or female aged 18 65 years. * Appropriate clinical data to enable classification into sepsis or SIRS according to Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). * Written informed consent by the patient or guardian

Exclusion criteria

* No informed consent * Renal failure * Liver failure * Hematologic diseases * Neutropenia * Malignancy * Chemotherapy during the previous 90 days. * Patients using antibiotics at presentation

Design outcomes

Primary

Measure	Time frame
Mortality during intensive care unit stay	28 days

Secondary

Measure	Time frame
Need for readmission to ICU	assessed up to 3 months
Ventilatory support duration	assessed up to 3 months
Length of ICU stay	assessed up to 3 months
Number of participants who need inotropic or vasopressor support	assessed up to 3 months
Transfusion requirements (blood and blood products)	assessed up to 3 months
Number of participants who need renal replacement therapy	assessed up to 3 months

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026